Company Expects FY26 Adjusted EBITDA of At Least $300M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy IRWD?
Sees FY26 adjusted EBITDA at least $300M. The company said, "As we enter 2026, we remain focused on our core priorities of maximizing LINZESS, advancing apraglutide and delivering sustained profits and cash flows. We believe our full-year 2026 financial guidance demonstrates the significant progress we've made across these priorities and our ability to drive increasing shareholder value. In 2026, we expect increased LINZESS U.S. Net Sales and disciplined expense management to drive greater than $300 million in adjusted EBITDA, enabling us to continue advancing apraglutide and reduce our debt to further strengthen our financial position. We believe apraglutide has the potential to redefine the standard of care for patients living with SBS-IF and look forward to initiating sites for the confirmatory Phase 3 clinical trial, STARS-2, in the second quarter of this year. With an improved financial position, we now have a clear path to execute our strategy, and we continue to evaluate all options to maximize shareholder value."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRWD
Wall Street analysts forecast IRWD stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.570
Low
5.00
Averages
6.23
High
8.00
Current: 3.570
Low
5.00
Averages
6.23
High
8.00
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ironwood (IRWD) Q4 2025 Earnings Call Transcript
See More
Ironwood Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: Ironwood Pharmaceuticals reported a Q4 non-GAAP EPS of -$0.01, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: Q4 revenue of $47.71 million fell 47.3% year-over-year and missed the expected $52 million, reflecting weak market demand and increased competition, which could pressure future performance.
- 2026 Sales Guidance: The company projects U.S. LINZESS net sales between $1.125 billion and $1.175 billion in 2026, driven by improved net pricing and low-single digit demand growth, demonstrating long-term confidence in the product.
- Overall Revenue Outlook: Ironwood anticipates total revenue of $450 million to $475 million for 2026, exceeding the consensus of $410.5 million, indicating an optimistic view on future growth despite current underperformance.
See More
Ironwood Reports 2025 Financial Highlights and 2026 Guidance
- LINZESS Demand Growth: In 2025, LINZESS experienced an 11% year-over-year growth in EUTRx demand, further solidifying its position as the prescription market leader for IBS-C and CIC treatment, having treated over 5.7 million unique patients to date, indicating strong market demand and brand recognition.
- Strong Financial Performance: Ironwood reported total revenues of $296 million and GAAP net income of $24 million for 2025, with adjusted EBITDA of $138 million, demonstrating the company's ability to maintain profitability while effectively managing expenses, thereby strengthening its foundation for future investments.
- Positive 2026 Outlook: The company expects U.S. net sales of LINZESS to range between $1.125 billion and $1.175 billion in 2026, with adjusted EBITDA projected to exceed $300 million, reflecting confidence in LINZESS's continued growth and the advancement of the new drug apraglutide, aimed at enhancing shareholder value.
- Clinical Trial Progress: The confirmatory Phase 3 clinical trial design for apraglutide has been finalized, with site initiations expected to begin in the second quarter of 2026, which, if successful, could redefine the standard of care for patients with short bowel syndrome, showcasing Ironwood's strategic focus on innovative drug development.
See More
Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro
- Investment Resumption: President Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry following the ousting of Maduro, aiming to restore the country's dilapidated oil infrastructure and stimulate economic recovery.
- Oil Price Fluctuations: Following geopolitical developments, WTI February futures traded 0.05% lower at $57.29 per barrel early Monday, indicating market caution regarding future oil price trends.
- Market Expectations: The CME Group's FedWatch tool indicates an 82.3% likelihood that the Federal Reserve will keep interest rates unchanged in January, which could influence investor confidence in the stock market.
- Stock Market Performance: In premarket trading on Monday, the SPDR S&P 500 ETF (SPY) rose 0.22% to $684.68, while the Invesco QQQ Trust ETF (QQQ) increased by 0.51% to $616.26, reflecting optimistic sentiment regarding economic recovery.
See More
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
- Market Performance: Health care stocks showed mixed results on Friday afternoon, with the NYSE Health Care Index inching higher, reflecting a cautious optimism among investors regarding the health sector despite ongoing economic uncertainties.
- Investor Sentiment: While some health care stocks gained, the overall market sentiment remains complex as investors assess macroeconomic factors that could impact the health industry alongside industry-specific developments.
- Industry Dynamics: The volatility within the health sector highlights investor sensitivity to policy changes and market demand, particularly in the current economic climate, where the performance of health stocks may influence broader investment strategies.
- Future Outlook: As the health sector faces both challenges and opportunities, investors need to closely monitor relevant policies and market trends to make more informed investment decisions moving forward.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
Ironwood (IRWD) Q4 2025 Earnings Call Transcript
See More
Ironwood Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: Ironwood Pharmaceuticals reported a Q4 non-GAAP EPS of -$0.01, missing expectations by $0.02, indicating challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: Q4 revenue of $47.71 million fell 47.3% year-over-year and missed the expected $52 million, reflecting weak market demand and increased competition, which could pressure future performance.
- 2026 Sales Guidance: The company projects U.S. LINZESS net sales between $1.125 billion and $1.175 billion in 2026, driven by improved net pricing and low-single digit demand growth, demonstrating long-term confidence in the product.
- Overall Revenue Outlook: Ironwood anticipates total revenue of $450 million to $475 million for 2026, exceeding the consensus of $410.5 million, indicating an optimistic view on future growth despite current underperformance.
See More
Ironwood Reports 2025 Financial Highlights and 2026 Guidance
- LINZESS Demand Growth: In 2025, LINZESS experienced an 11% year-over-year growth in EUTRx demand, further solidifying its position as the prescription market leader for IBS-C and CIC treatment, having treated over 5.7 million unique patients to date, indicating strong market demand and brand recognition.
- Strong Financial Performance: Ironwood reported total revenues of $296 million and GAAP net income of $24 million for 2025, with adjusted EBITDA of $138 million, demonstrating the company's ability to maintain profitability while effectively managing expenses, thereby strengthening its foundation for future investments.
- Positive 2026 Outlook: The company expects U.S. net sales of LINZESS to range between $1.125 billion and $1.175 billion in 2026, with adjusted EBITDA projected to exceed $300 million, reflecting confidence in LINZESS's continued growth and the advancement of the new drug apraglutide, aimed at enhancing shareholder value.
- Clinical Trial Progress: The confirmatory Phase 3 clinical trial design for apraglutide has been finalized, with site initiations expected to begin in the second quarter of 2026, which, if successful, could redefine the standard of care for patients with short bowel syndrome, showcasing Ironwood's strategic focus on innovative drug development.
See More
Trump Announces U.S. Oil Companies to Invest Billions in Venezuela Post-Maduro
- Investment Resumption: President Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry following the ousting of Maduro, aiming to restore the country's dilapidated oil infrastructure and stimulate economic recovery.
- Oil Price Fluctuations: Following geopolitical developments, WTI February futures traded 0.05% lower at $57.29 per barrel early Monday, indicating market caution regarding future oil price trends.
- Market Expectations: The CME Group's FedWatch tool indicates an 82.3% likelihood that the Federal Reserve will keep interest rates unchanged in January, which could influence investor confidence in the stock market.
- Stock Market Performance: In premarket trading on Monday, the SPDR S&P 500 ETF (SPY) rose 0.22% to $684.68, while the Invesco QQQ Trust ETF (QQQ) increased by 0.51% to $616.26, reflecting optimistic sentiment regarding economic recovery.
See More
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
- Market Performance: Health care stocks showed mixed results on Friday afternoon, with the NYSE Health Care Index inching higher, reflecting a cautious optimism among investors regarding the health sector despite ongoing economic uncertainties.
- Investor Sentiment: While some health care stocks gained, the overall market sentiment remains complex as investors assess macroeconomic factors that could impact the health industry alongside industry-specific developments.
- Industry Dynamics: The volatility within the health sector highlights investor sensitivity to policy changes and market demand, particularly in the current economic climate, where the performance of health stocks may influence broader investment strategies.
- Future Outlook: As the health sector faces both challenges and opportunities, investors need to closely monitor relevant policies and market trends to make more informed investment decisions moving forward.
See More
Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%
- Capital Raising Announcement: Intelligent Bio Solutions revealed plans to raise $10 million through a private placement, which led to a sharp 19.7% decline in its stock price during Friday's session, indicating a negative impact on investor confidence and market performance.
- Stock Price Reaction: Following the announcement, shares of Intelligent Bio fell to $7.65, reflecting market concerns regarding the company's future financial health and potentially affecting its ability to secure further funding.
- Market Dynamics: While Intelligent Bio's stock plummeted, other stocks such as Lavoro Limited and Ironwood Pharmaceuticals surged by 181% and 57.7% respectively, highlighting a divergence in market performance among different companies.
- Investor Focus: The announcement of this capital raising plan may prompt investors to reassess Intelligent Bio's strategic direction, particularly in the current market environment where the necessity and timing of fundraising are critically important.
See More
